Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 3, 2015, Pages 489-498

  Fogelman, David ^e   Sugar, Elizabeth A ^b,d   Oliver, George ^b,f   Shah, Neeraj ^e,g   Klein, Alison ^b,c,d,h   Alewine, Christine ^c,i   Wang, Huamin ^j   Javle, Milind ^e   Shroff, Rachna ^e   Wolff, Robert A ^e   Abbruzzese, James L ^e,k   Laheru, Daniel ^b   Diaz, Luis A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Staten Island University Hospital ^*  (United States)

^g STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j Unit 0085   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

BRCA; Chemotherapy; Family history; Pancreatic adenocarcinoma; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM; PLATINUM COMPLEX;

ADULT; AGED; BREAST CANCER; CANCER PATIENT; DRUG SENSITIVITY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PEDIGREE; PRIORITY JOURNAL; REVIEW; CANCER STAGING; FAMILY HEALTH; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FAMILY HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84939566713     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2788-6     Document Type: Review

References (32)

1. Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
2. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 364:1817-1825
3. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 369:1691-1703
4. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
5. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr (2012) A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 69(2):415-424. doi: 10.1007/s00280-011-1704-y
6. Kriege M, Seynaeve C, Meijers-Heijboer H et al (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:3764-3771
7. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361:123-134
8. Taniguchi T, Tischkowitz M, Ameziane N et al (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574
9. James E, Waldron-Lynch MG, Saif MW (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 20:634-638
10. Chalasani P, Kurtin S, Dragovich T (2008) Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP 9:305-308
11. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917
12. van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508-7515
13. Tischkowitz MD, Sabbaghian N, Hamel N et al (2009) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137:1183-1186
14. Al-Sukhni W, Rothenmund H, Borgida AE et al (2008) Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 124:271-278
15. Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167
16. Couch FJ, Johnson MR, Rabe K et al (2005) Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383-386
17. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588
18. Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342-346
19. Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480-1490
20. Breast Cancer Linkage C (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
21. Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364
22. Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609
23. Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132-1138
24. Sonnenblick A, Kadouri L, Appelbaum L et al (2011) Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12:165-168
25. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195
26. Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390
27. Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663
28. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379
29. Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401-405
30. Mukhopadhyay A, Elattar A, Cerbinskaite A et al (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16:2344-2351
31. Heinemann V, Wilke H, Mergenthaler HG et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403
32. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516